Logo image of ONC.CA

ONCOLYTICS BIOTECH INC (ONC.CA) Stock Price, Quote, News and Overview

TSX:ONC - Toronto Stock Exchange - CA6823108759 - Common Stock - Currency: CAD

1.09  -0.05 (-4.39%)

ONC.CA Quote, Performance and Key Statistics

ONCOLYTICS BIOTECH INC

TSX:ONC (2/7/2025, 7:00:00 PM)

1.09

-0.05 (-4.39%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.08
52 Week Low0.98
Market Cap84.01M
Shares77.07M
Float74.13M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-01 2000-06-01


ONC.CA short term performance overview.The bars show the price performance of ONC.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20

ONC.CA long term performance overview.The bars show the price performance of ONC.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ONC.CA is 1.09 CAD. In the past month the price decreased by -12.8%. In the past year, price decreased by -21.58%.

ONCOLYTICS BIOTECH INC / ONC Daily stock chart

ONC.CA Latest News and Analysis

News Image
17 days ago - FinancialNewsMedia

Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NASDAQ:GILD),(NYSE:BMY) EQNX::TICKER_END

News Image
17 days ago - FinancialNewsMedia

Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Pelareorep combination therapy shows continued meaningful improvement over checkpoint inhibitors alone in anal cancer patients   Pelareorep-based therapy demonstrates strong safety profile with new chemotherapy regimen in pancreatic cancer patients   SAN DIEGO, CA and CALGARY, AB – January 22, 2025 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in […]

News Image
a month ago - FinancialNewsMedia

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

ONC.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
FRX.CA FENNEC PHARMACEUTICALS INC N/A 247.78M
BCT.CA BRIACELL THERAPEUTICS CORP N/A 236.47M
EDT.CA SPECTRAL MEDICAL INC N/A 166.88M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 163.85M
TH.CA THERATECHNOLOGIES INC N/A 105.75M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 99.26M
COV.CA COVALON TECHNOLOGIES LTD 28.09 84.67M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 79.27M
MBX.CA MICROBIX BIOSYSTEMS INC 16.5 66.59M
SVA.CA SERNOVA CORP N/A 55.07M
HBP.CA HELIX BIOPHARMA CORP N/A 44.12M
MDCX.CA MEDICUS PHARMA LTD N/A 41.77M

About ONC.CA

Company Profile

ONC logo image Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2000-06-01. The firm is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Company Info

ONCOLYTICS BIOTECH INC

804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7

Calgary ALBERTA T2N 1X7 CA

CEO: Matthew C. Coffey

Employees: 29

Company Website: https://www.oncolyticsbiotech.com/

Investor Relations: http://www.oncolyticsbiotech.com/investor-centre/investor-overview/

Phone: 14036707377

ONC.CA FAQ

What is the stock price of ONC.CA?

The current stock price of ONC.CA is 1.09 CAD.


What is the symbol for ONCOLYTICS BIOTECH INC stock?

The exchange symbol of ONCOLYTICS BIOTECH INC is ONC and it is listed on the Toronto Stock Exchange exchange.


On which exchange is ONC.CA stock listed?

ONC.CA stock is listed on the Toronto Stock Exchange exchange.


Is ONC.CA a good stock to buy?

Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ONC.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ONC.CA.


Does ONC.CA stock pay dividends?

ONC.CA does not pay a dividend.


ONC.CA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ONC.CA Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

ONC.CA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to ONC.CA. The Buy consensus is the average rating of analysts ratings from 11 analysts.


Ownership
Inst Owners1.69%
Ins Owners3.58%
Short Float %N/A
Short RatioN/A
Analysts
Analysts80
Price Target6.53 (499.08%)
EPS Next YN/A
Revenue Next YearN/A